Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 260 clinical trials
Featured trial
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Our team of medical professionals is evaluating an investigational drug that is designed to slow the progression of Alzheimer’s disease. The study drug, ALZ-801, is a tablet that is taken twice daily. It has been well tolerated in earlier studies and may be a convenient option for Alzheimer’s patients and …

mild dementia
dementia
mini-mental state examination
apolipoprotein e
  • 76 views
  • 20 Sep, 2022
  • 79 locations
Featured trial
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

  • 142 views
  • 03 Oct, 2019
  • 1 location
Featured trial
Ascend-Nash: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Crv431 In Adult Subjects With Nonalcoholic Steatohepatitis And Advanced Liver Fibrosis

biopsy-proven nonalcoholic steatohepatitis (NASH) and stage 2 liver fibrosis (F2) / stage 3 liver fibrosis (F3).Exploratory:To validate the use of a composite NASH multi-omics AI-POWR™ biomarker

  • 0 views
  • 29 Sep, 2022
  • 1 location
Featured trial
Fatty Liver Disease Research Study Enrolling

Fatty Liver Disease Research Study Enrolling

  • 195 views
  • 23 Nov, 2020
  • 1 location
Featured trial
TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

  • 426 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

  • 237 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • 1167 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • 446 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A clinical trial to evaluate the safety of NLRP3i (inhibitor of a protein called NLRP3) and how it affects the body and brain of people living with early-stage Parkinson’s disease.

This is a Phase 1b study conducted in the US, the UK, and the Netherlands and aiming to better understand the safety of an oral drug in a capsule form which includes a substance called NLRP3 inhibitor. The study aims to understand how the NLRP3 inhibitor affects the body and …

dementia
brain stimulation
cancer
alpha-synuclein
levodopa
  • 1 views
  • 17 Mar, 2023
  • 15 locations
Featured trial
AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • 492 views
  • 25 Mar, 2021
  • 1 location